The Future of Biological Therapies in COPD
Arch Bronconeumol (Engl Ed). 2018 Apr;54(4):185-186.
doi: 10.1016/j.arbres.2017.11.004.
Epub 2017 Dec 29.
[Article in
English,
Spanish]
Affiliation
- 1 Servicio de Neumología, Hospital del Mar. IMIM. DCEXS, Universitat Pompeu Fabra, CIBERES, ISCIII, Barcelona, España. Electronic address: quim.gea@upf.edu.
No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antibody Specificity
-
Asthma / complications
-
Asthma / immunology
-
Asthma / therapy
-
Biological Therapy* / adverse effects
-
Biological Therapy* / methods
-
Cytokines / antagonists & inhibitors
-
Cytokines / immunology
-
Humans
-
I-kappa B Kinase / antagonists & inhibitors
-
Inflammation Mediators / antagonists & inhibitors
-
Inflammation Mediators / immunology
-
Microbiota / drug effects
-
Molecular Targeted Therapy*
-
NF-kappa B / antagonists & inhibitors
-
Pulmonary Disease, Chronic Obstructive / complications
-
Pulmonary Disease, Chronic Obstructive / immunology
-
Pulmonary Disease, Chronic Obstructive / microbiology
-
Pulmonary Disease, Chronic Obstructive / therapy*
-
Th1 Cells / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Cytokines
-
Inflammation Mediators
-
NF-kappa B
-
I-kappa B Kinase